Reduced tyrosine kinase receptor C mRNA levels in the frontal cortex of patients with schizophrenia

Neurosci Lett. 1998 Nov 27;257(2):65-8. doi: 10.1016/s0304-3940(98)00807-6.

Abstract

Using a quantitative RNA-PCR approach tyrosine kinase receptor (trk) C mRNA levels were determined in brain material from the frontal cortex (BA10), temporal cortex (BA20) and cerebellum of control specimen and patients with schizophrenia, bipolar disorder or non-psychotic depression (15 subjects each). In the frontal cortex of schizophrenics there was a 5.8-fold reduction of trk C mRNA levels, which reached statistical significance (P < 0.05). Trk C levels in the cerebellum were positively correlated with lifetime fluphenazine equivalents (r = 0.54), suggesting that neuroleptics influence TRK C gene activity in the cerebellum. Moreover, the distinct medication-independent reduction of trk C mRNA may point to a disturbed neurotrophic gene activity in the frontal cortex of schizophrenic patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / therapeutic use
  • Bipolar Disorder / metabolism
  • Cerebellum / metabolism
  • Depressive Disorder / metabolism
  • Female
  • Fluphenazine / administration & dosage
  • Fluphenazine / therapeutic use
  • Frontal Lobe / metabolism*
  • Humans
  • Male
  • Middle Aged
  • RNA, Messenger / metabolism*
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Receptor, trkC
  • Receptors, Nerve Growth Factor / genetics*
  • Reference Values
  • Schizophrenia / metabolism*
  • Temporal Lobe / metabolism

Substances

  • Antipsychotic Agents
  • RNA, Messenger
  • Receptors, Nerve Growth Factor
  • Receptor Protein-Tyrosine Kinases
  • Receptor, trkC
  • Fluphenazine